Inflammation resultant from tumor growth, infection with certain pathogens, or in some cases,
trauma, can result in systemic release of cytokines, especially GM-CSF, that in turn stimulate …

In the era of novel agents and immunotherapies in solid and liquid tumors, there is an
emerging need to understand the cross-talk between the neoplastic cells, the host immune …

Tumor-associated myeloid cells have been implicated in regulating many of the “hallmarks
of cancer” and thus fostering solid tumor development and metastasis. However, the same …

Immune function relies on an appropriate balance of the lymphoid and myeloid responses.
In the case of neoplasia, this balance is readily perturbed by the dramatic expansion of …

Cancer is the outcome of the conflict between the host immune system and cancer cells. The
crosstalk between immune cells and tumor cells within the tumor microenvironment (TME) …

Hematologic malignancies provide a suitable testing environment for cell-based
immunotherapies, which were pioneered by the development of allogeneic hematopoietic …

Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and
immune checkpoint inhibitors, have emerged as promising modalities in multiple …

Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with
poor overall survival. While some malignancies have seen improvements in clinical …

With the major advances in cancer immunology and immunotherapy, it is critical to consider
that most immune cells are short-lived and need to be continuously replenished from …

Immune responses generated against malignant cells have the potential to inhibit tumor
growth, or even eliminate transformed cells before a tumor forms. However, immune …